IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.
Ranks and profiles the top 15 US biotech incubators and accelerators for 2026, comparing funding and equity terms, lab space models, university affiliated programs, and AI drug discovery venture accelerators.
A 2026 analyst comparison of 8 pharmaceutical stability chamber manufacturers including Binder, Memmert, Thermo Fisher, Weiss Technik, and ESPEC, covering ICH Q1A(R2) conditions, walk-in room sizing, and market data.
A 2026 analyst comparison of the top HPLC system manufacturers including Waters, Agilent, Thermo Fisher, and Shimadzu, covering UHPLC pressure specs up to 1,500 bar, CDS software options, and market size data from six research firms.
A 2026 analyst comparison of the top lyophilization CDMOs, including Catalent, Lonza, Simtra, Vetter, and PCI Pharma Services, covering freeze-dryer capacity, sterile fill-finish specs, recent capacity investments, and how to choose a partner.
A 2026 analyst ranking of the top 10 sterile fill-finish CDMOs, covering isolator vs RABS technology, prefilled syringe capacity, EU Annex 1 compliance, and capital investment data for Lonza, Thermo Fisher, Catalent, and more.
A 2026 analyst ranking of the top 10 mass spectrometry manufacturers, covering Thermo Fisher, Agilent, Waters, Bruker, and Shimadzu, with market size data, revenue figures, and proteomics platform benchmarks.
A 2026 comparison of the top 10 electronic lab notebook (ELN) platforms, covering Benchling, LabArchives, SciNote, and Dotmatics, with pricing, 21 CFR Part 11 compliance, and free ELN options.
A 2026 analyst ranking of the top CDMO companies by revenue and capacity, covering Lonza, Samsung Biologics, WuXi Biologics, and Thermo Fisher, plus CDMO vs CMO vs CRO differences and $150B+ market data.
A 2026 analyst comparison of Illumina vs Thermo Fisher Ion Torrent NGS platforms, covering SBS vs ion semiconductor chemistry, accuracy benchmarks, cost per sample, clinical oncology use, and market share.
A 2026 analyst guide to pharmaceutical formulation development covering preformulation studies, BCS classification, solubility and bioavailability enhancement techniques, ICH Q1A(R2) stability testing, and five named case studies.
A 2026 analyst comparison of ADC CDMOs including Lonza, WuXi XDC, Catalent, Piramal, Abzena, and CordenPharma, covering conjugation capacity, HPAPI containment (OEB/OEL), and capital investment data.
A 2026 analyst guide to private LLM total cost of ownership in pharma: on-prem GPU capex, API pricing, GxP validation costs, break-even analysis, and five named deployments from Lilly, Roche, BMS, Amgen, and J&J.
A 2026 analyst guide to parenteral drug products, covering IV, IM and SC routes, vials versus prefilled syringes, autoinjectors and wearable injectors, and FDA and EU combination product rules.
2026 analyst comparison of ISO 14644-1 cleanroom classes and EU GMP Annex 1 Grades A-D, covering particle limits, viable-monitoring CFU limits, requalification cadence, and four named FDA enforcement and industry cases.
A 2026 analyst guide to dissolution testing and bioequivalence, covering f2 similarity factor calculation and its statistical limitations, USP apparatus types, BCS biowaiver rules under FDA, EMA, WHO and ICH M9, and IVIVC modeling.
A 2026 analyst guide to pharmaceutical excipients: FDA/EMA definitions, the 10 functional categories, drug-excipient compatibility testing methods, the FDA Novel Excipient Review Pilot Program, and a $10.7-11.0 billion market analysis.
Compares terminal sterilization and aseptic processing in pharmaceutical manufacturing as of 2026: SAL 10-6 vs 10-3, FDA/EMA/Annex 1 rules, USP 71 limits, market data, and 5 named cases.
A 2026 analyst comparison of clinical trial software covering CTMS, EDC, eTMF, eConsent, eCOA, and payments platforms including Veeva, Medidata, Oracle, IQVIA, Castor, Advarra, REDCap, and Signant Health, with pricing, market data, and FDA case studies.
A 2026 analyst guide to lyophilization cycle development, covering primary and secondary drying, collapse temperature testing, cake defect troubleshooting, freeze dryer scale up, and FDA/ICH process validation requirements.
A 2026 data report on radioligand therapy manufacturing capacity, covering Novartis's $23 billion US build-out, the CDMO landscape, and the lutetium-177 and actinium-225 isotope supply constraints limiting patient access.
A 2026 data report answering how many clinical trials use AI: ClinicalTrials.gov search counts, a 3,106-trial JMIR cohort, phase and sponsor breakdowns, market sizing, and FDA, EMA, and global regulatory data.
A 2026 analyst comparison of clinical trial patient recruitment vendors, covering AI matching platforms like Antidote and Deep 6 AI, site-network IROs, CRO divisions at IQVIA, ICON and Parexel, pricing models, cost benchmarks, and enrollment data.
A 2026 analyst comparison of viral vector and gene therapy CDMOs covering AAV manufacturing capacity, bioreactor scale up to 5,000L, regulatory track records, and 8 to 18 month lead times across Catalent, Lonza, and 10 other providers.
A 2026 analyst comparison of oral solid dosage forms covering tablets, capsules, orally disintegrating tablets, and modified-release systems, with FDA definitions, market sizing, and manufacturing detail.
© 2026 IntuitionLabs. All rights reserved.
